Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Persistent Post-Stroke and Vascular Headache
NCT04580238Phase 1Withdrawn
- Sponsor
- University of Alberta
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of botulinum toxin type A in headache attributed to stroke (2 arms), sponsored by University of Alberta. Primary endpoints: Change in Number of Migraine Days at 2 years, Change in Number of Moderate to Severe Migraine Days at 2 years and 1 more. Planned start Dec 2023; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
headache attributed to stroke
Beyond the preview
Go deeper on NCT04580238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580238.